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Abstract (word count: 247) 35 
 36 
Objective: Circulating adiponectin levels have been shown to be associated with risk of coronary 37 
heart disease (CHD). However, its primary role in protecting against the development of CHD 38 
remains controversial due to conflicting observations in prospective studies. To gain further insight 39 
into the primary role of adiponectin, our major objective was to investigate the relationship between 40 
single nucleotide polymorphisms (SNPs) of the adiponectin gene (ADIPOQ) and incident CHD in a 41 
population-based cohort with no CHD at baseline. 42 
 43 
Design and Methods: We conducted a 16-year longitudinal study in 2196 subjects from the Hong 44 
Kong Cardiovascular Risk Factors Prevalence Study (CRISPS). During 33,862 person-years of 45 
follow-up, 184 subjects developed CHD (cumulative incidence rate = 5.4 per 1000 person-years). 46 
Nine ADIPOQ SNPs with potential functional relevance or shown to be associated with adiponectin 47 
levels and/or CHD were genotyped.  48 
 49 
Results: Among the 9 ADIPOQ SNPs, +276G>T (rs1501299) was independently associated with 50 
incident CHD in men but not in women, even after adjustments for traditional cardiovascular risk 51 
factors (Padjusted = 5.5x10-3 to 0.023; Hazard ratio [HR] = 1.39 to 1.54). Furthermore, there was a 52 
significant association of the T allele of +276G>T with lower adiponectin level (P = 0.027; β[95%CI] 53 
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= -0.05[-0.10, -0.01]). 54 
 55 
Conclusions: This study demonstrated that +276G>T may be an independent predictor of CHD 56 
development. Our findings suggest that low adiponectin levels, as may be influenced by +276G>T, 57 
confer a higher risk of CHD, in keeping with a role of hypoadiponectinaemia in the development of 58 
CHD in the general population.  59 
 60 
 61 
 62 
63 
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Introduction 64 
Adiponectin is one of the most abundant insulin-sensitising adipokines secreted by the 65 
adipocytes (1). Circulating levels of adiponectin are reduced in obesity, in particular visceral obesity 66 
(2, 3), and predispose to endothelial dysfunction, atherosclerosis and subsequent cardiovascular 67 
diseases in animal models. Hypoadiponectinaemia has been proposed as one of the mediators of 68 
increased cardiovascular risk in obesity (4). Adiponectin, encoded by ADIPOQ, is suggested to play a 69 
protective role in the development of coronary heart disease (CHD) due to its anti-inflammatory, 70 
anti-oxidative, anti-apoptotic, and anti-atherogenic properties (3, 5). The prospective relationship 71 
between circulating adiponectin level and the developement of CHD has been extensively 72 
investigated. However, whether adiponectin levels are causally related to CHD development remains 73 
controversial. While high adiponectin levels are believed to be protective against CHD in healthy 74 
populations (6), more recent studies suggest that high adiponectin levels are linked with a greater risk 75 
of CHD or cardiovascular mortality in older populations (7) or cohorts with prevalent CHD (8). As the 76 
up-regulation of adiponectin could act as a compensatory mechanism to limit further vascular injury 77 
(8), a high adiponectin level in the established disease state might reflect on the severity of the 78 
underlying vascular inflammation, and hence a positive association between the adiponectin level and 79 
cardiovascular mortality. 80 
 81 
Studies of potentially functional ADIPOQ genetic variants may provide more insight into the 82 
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primary role of adiponectin, if any, in protecting against the development of CHD. So far, only a few 83 
prospective studies conducted in Caucasians have investigated the genetic effects of ADIPOQ SNPs 84 
on CHD development (9, 10, 11). The primary objective of this study was to evaluate the impact of 9 85 
ADIPOQ single nucleotide polymorphisms (SNPs) on the risk of CHD in a 16-year longitudinal study 86 
cohort of healthy Southern Chinese. These SNPs were selected because of their potential functional 87 
relevance or reported influence on the risk of CHD or cardiovascular diseases (CVD) and/or 88 
adiponectin levels. 89 
 90 
Methods 91 
Subjects 92 
The Hong Kong Cardiovascular Risk Factors Prevalence Study (CRISPS) is a population-based 93 
prospective study of cardiovascular risk factors in Hong Kong (12). In 1995-1996 (CRISPS1), 2895 94 
Hong Kong Chinese were selected randomly by their telephone numbers to undergo a comprehensive 95 
assessment of cardiovascular risks. Subjects were contacted for reassessment in 2000-2004 (CRISPS2) 96 
and in 2005-2008 (CRISPS3). The latest CRISPS4 follow-up assessment was commenced in July 97 
2010. The current study involved a total of 2196 subjects who did not have a history of CHD at 98 
baseline (CRISPS1) and with DNA samples available for genetic analysis. During 33,862 person-years 99 
of follow-up, 184 subjects (111 men and 73 women) who were non-CHD at baseline had developed 100 
CHD by the end of 2011, giving a cumulative incidence rate of 5.4 per 1000 person-years. 2012 101 
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subjects (915 men and 1097 women) who were non-CHD at baseline had remained as non-CHD at 102 
subsequent follow-up visit(s). CHD events were defined based on ICD-9 (402, 404, 410-414, 425-429) 103 
which included, among others, acute myocardial infarction (MI), heart failure, and angina pectoris as 104 
described in our previous study (13). Information on the dates of the CHD events and discharge 105 
diagnosis were obtained from the patients and also verified from the Hospital Authority database or 106 
the patients’ private practitioners. For those who had died, causes and dates of death were determined 107 
from the Hong Kong Death Registry database. Two physicians reviewed the medical diagnoses 108 
independently; disagreements between them were resolved by a third physician. The concordance 109 
between the two physicians was 0.98. Written informed consent was obtained from each participant 110 
and the study protocol was approved by the Ethics Committee of the University of Hong Kong. 111 
 112 
Anthropometric and biochemical measurements 113 
Anthropometric (including body mass index [BMI], waist circumference (WC), systolic blood 114 
pressure [SBP] and diastolic blood pressure [DBP]) and biochemical parameters (including fasting 115 
plasma glucose [FPG], 2-h post-OGTT glucose [2hrG], triglyceride [TG], high-density lipoprotein 116 
cholesterol [HDL-C]; low-density lipoprotein cholesterol [LDL-C] and total cholesterol [TC]) were 117 
measured as previously described (14). Type 2 Diabetes (DM) was defined as FPG ≥ 7.0mmol/l or 118 
2hrG ≥ 11.1mmol/l or both, according to the World Health Organization 1998 diagnostic criteria (15); 119 
or on anti-diabetic medication. At baseline, 181 subjects (89 men and 90 women) had DM and 1923 120 
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subjects (904 men and 1017 women) were non-DM. The presence of hypertension (HT) was defined 121 
as BP ≥ 140/90mmHg or receiving regular anti-hypertensive treatment. The presence of dyslipidaemia 122 
was defined as fasting TG ≥ 1.69mmol/l, HDL-C < 1.04mmol/l in male and < 1.29mmol/l in female), 123 
and LDL-C ≥ 3.4mmol/l (16), or taking lipid-lowering agents. Since stored baseline plasma samples 124 
were no longer available from a large number of subjects, total adiponectin level was measured in 125 
available plasma samples collected at the CRISPS2 follow-up visit (n=1676), using an in-house 126 
sandwich ELISA kit established in our laboratory (intra-assay and inter-assay coefficients of variation 127 
of 6.2–8.3% and 5.1–6.4% respectively) (17).  128 
 129 
Genetic analysis 130 
A total of 9 ADIPOQ SNPs (rs16861194, rs266729 [-11377C>G], -10677C>T, rs1802052 131 
[-10066G>A], rs822395 [-4034A>C], rs822396 [-3964A>G], rs12495941, rs2241766 [+45T>G], and 132 
rs1501299 [+276G>T]) were selected on the basis of previous publications suggesting them as 133 
functional (18, 19, 20), or shown to affect adiponectin levels (9, 21, 22, 23), or associated with 134 
CHD/CVD (9, 11, 24). Genotyping of these SNPs was performed using the Sequenom iPLEX Gold 135 
genotyping assay at the Centre for Genomic Sciences, the University of Hong Kong. The average 136 
genotyping call rate and concordance rate were 99.8% and 97.5%, respectively. The SNPs were tested 137 
for deviation from Hardy Weinberg Equilibrium (HWE) by the De Finetti program available online at 138 
<http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl>. 139 
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 140 
Statistical Analysis 141 
All statistical analyses were conducted with SPSS version 19.0 (Chicago, Illinois). The 142 
associations of SNPs with incident CHD were evaluated using Cox proportional hazards regression 143 
(Cox-regression) analyses under the additive model. Survival was calculated from the date of visit at 144 
baseline to the date of diagnosis of CHD or the date of last follow-up visit. In view of the known 145 
gender difference in adiponectin levels (25) and the observation of a higher incidence rate of CHD in 146 
men (7.1 per 1000 person years versus 4.0 per 1000 person years in women), we also performed 147 
gender-stratified analyses. A two-tailed P < 0.05 was considered as statistically significant. Baseline 148 
clinical parameters that were biologically likely to have an influence on the development of CHD or 149 
were statistically different (P < 0.05) between the incident CHD and non-CHD groups were adjusted 150 
for in the multiple adjustment analyses. Three different sets of traditional risk factors were included in 151 
the multiple Cox-regression analyses. Multiple adjustments for age, BMI, 2hrG, HOMA-IR, HDL-C, 152 
LDL-C, TG, SBP, DBP and smoking were made in Model 1; adjustments were made for age, BMI, 153 
FPG, 2hrG, HDL-C, LDL-C, TG, SBP, DBP and smoking in Model 2; and adjustments were made for 154 
age, BMI, DM, dyslipidaemia, HT and smoking in Model 3. Logistic regression analysis was 155 
employed to examine the association of +276G>T with DM at baseline. The association of +276G>T 156 
with plasma adiponectin level at CRISPS2 was evaluated by linear regression analysis. The 157 
associations of CRISPS2 adiponectin levels with the development of CHD were evaluated using 158 
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Cox-regression analyses. Survival was calculated from the date of visit at CRISPS2 to the date of 159 
diagnosis of CHD or the date of last follow-up visit. Both combined and gender-stratified analyses 160 
were performed. The study power was calculated using the Genetic Power Calculator (26).  161 
 162 
Results 163 
Baseline clinical characteristics 164 
 We examined the associations of 9 ADIPOQ genetic variants with incident CHD in 2196 165 
subjects with DNA samples available for genetic analysis. Among these subjects who were non-CHD 166 
at baseline, 184 subjects (cumulative incidence rate = 5.4 per 1000 person years) developed CHD 167 
during 33,862 person-years of follow-up; 2012 subjects remained free of CHD at subsequent 168 
follow-up visit(s). Table 1 show the baseline clinical characteristics of the subjects. In both genders, 169 
the incident CHD groups had worse traditional cardiovascular risk factors, such as the presence of 170 
DM, dyslipidaemia and HT, when compared with the non-CHD groups. However there were no 171 
significant differences in regular exercise, alcohol drinking, and family history of DM, HT and CHD. 172 
 173 
Association with CHD development 174 
The allele frequencies of the 9 SNPs were comparable to those reported in HapMap or 1000 175 
Genome Project (Table 2). The genotype distributions of these SNPs were in HWE (P = 0.071-0.809). 176 
Among these SNPs, rs1501299 (+276G>T) showed a significant association with incident CHD 177 
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(Punadjusted = 0.042; HR[95%CI]: 1.26[1.01-1.56]). When stratified by gender, the association of 178 
+276G>T variant with incident CHD remained significant in men (Punadjusted = 0.020; HR[95%CI]: 179 
1.39[1.05-1.83]). However, no significant association was found in women (Punadjusted = 0.816; 180 
HR[95%CI]: 1.04[0.73-1.50]). No significant associations of the other SNPs with incident CHD were 181 
observed in either gender.  182 
 183 
Independent association of +276G>T with incident CHD in men   184 
The possible independent association of +276G>T with incident CHD in men was further 185 
analysed with adjustments for different sets of traditional risk factors, including DM and its related 186 
traits, as the +276G>T variant was independently associated with DM at baseline, even after 187 
adjustment for age, sex and BMI in this study (Page, sex and BMI-adjusted = 2x10-3, OR[95%CI]: 188 
1.45[1.14-1.84]). Table 3 shows the results of the multiple Cox-regression analyses in the male 189 
subjects. +276G>T showed a significant association with incident CHD in men after adjustment for 190 
age, BMI, 2hrG, HOMA-IR, HDL-C, LDL-C, TG, SBP, DBP and smoking (Model 1) (Padjusted = 191 
5.5x10-3; HR[95%CI]: 1.54[1.13-2.08]). Figure 1 shows the cumulative survival curves for incident 192 
CHD in men, based on multiple adjustment model 1 and stratified by the +276G>T genotypes. The 193 
male subjects with the TT genotype had significantly higher risk of developing CHD than those with 194 
the GG or GT genotypes as shown in Figure 1 (Padjusted = 5.5x10-3). The association was also 195 
significant in adjustment Model 2 (Page, BMI, FPG, 2hrG, HDL-C, LDL-C, TG, SBP, DBP and smoking adjusted = 0.015; 196 
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HR[95%CI]: 1.44[1.08 -1.93]). Furthermore, when the presence of DM, dyslipidaemia and HT were 197 
included in the adjustment model in addition to age, BMI, and smoking (Model 3), the association 198 
persisted (Padjusted = 0.023; HR[95%CI]: 1.39[1.05-1.84]). In contrast, as expected, no significant 199 
association of +276G>T with incident CHD was observed in women (Model 1: Padjusted = 0.539; 200 
HR[95%CI]: 0.88[0.58-1.33]; Model 2: Padjusted = 0.381; HR[95%CI]: 0.83[0.56-1.13]; Model 3: 201 
Padjusted = 0.339; HR[95%CI]: 0.84[0.58-1.21]). 202 
 203 
Association of the +276G>T variant with plasma adiponectin level at CRISPS2 204 
Adiponectin level was found to be significantly lower (P<0.001) in men (median[interquartile 205 
range]: 5.62[3.62-8.69]mg/l, n=804) than in women (7.89[5.37-11.78]mg/l; n=872). We observed a 206 
significant association of the T allele of +276G>T with lower adiponectin level (P = 0.027; β[95%CI] 207 
= -0.05[-0.10, -0.01]) in 1676 subjects with available plasma samples. When the association was 208 
examined in men and women separately, we observed a significant association in men (P = 0.049; 209 
β[95%CI] = -0.07[-0.14, 0.00]), but the association was not significant in women (P = 0.424; 210 
β[95%CI] = -0.03[-0.09, 0.04]). Supplementary table 1 shows the comparison of adiponectin levels at 211 
CRISPS2 between different genotypes of +276G>T. Similar findings were obtained when subjects 212 
who had developed CHD by CRISPS2 were excluded.  213 
 214 
Association of plasma adiponectin level at CRISPS2 with the development of CHD after a 215 
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median interval of ~9.6 years 216 
We further examined the association of plasma adiponectin levels at CRISPS2 with the 217 
development of CHD, after a median interval of ~9.6 years. Since 46 of the 1676 subjects with 218 
adiponectin levels available for analysis had developed CHD by CRISPS2, only 1630 subjects were 219 
included in the analysis. Over a median interval of ~9.6 years, 101 subjects (56 men and 45 women) 220 
had developed CHD, while 1529 subjects (720 men and 809 women) remained free of CHD. We did 221 
not observe a significant association between CRISPS2 adiponectin level and CHD development, in 222 
both the combined (P = 0.200; HR[95%CI] = 0.82[0.60-1.11]) and gender-stratified analyses (Men: P 223 
= 0.465; HR[95%CI] = 0.85[0.60-1.30]; Women: P = 0.665; HR[95%CI] = 0.89[0.54-1.48] ). 224 
 225 
Discussion 226 
In this study, we observed a significant association of +276G>T with CHD development in men 227 
in a general population, independent of conventional cardiovascular risk factors. Consistent with 228 
previous cross-sectional studies (27, 28, 29), the +276G>T variant showed a significant association 229 
with DM in our cohort. The current study demonstrated that the +276G>T variant was independently 230 
associated with incident CHD in men, even after adjustment for DM or its related traits, together with 231 
other potential confounding factors, in the different multiple adjustment models. We also observed 232 
that +276G>T was associated with lower plasma adiponectin in this Chinese population, as was 233 
previously reported in studies amongst Italians (21) and Greeks (23). Our findings suggest that low 234 
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adiponectin levels, as influenced by a genetic variant in the ADIPOQ gene, confer a higher risk of 235 
CHD, in keeping with a role of low circulating adiponectin levels in the development of CHD. 236 
  237 
The T allele of +276G>T was previously found to be associated with CHD in case-control 238 
cross-sectional studies amongst Chinese (24), Italians (21) and Greeks (23). The current study has 239 
further provided evidence for its association with an increased risk of developing CHD in a 240 
population-based cohort, likely through a reduction in adiponectin expression. Intriguingly, a 241 
significant association of the +276G>T variant with incident CHD was only present in the male 242 
subjects of our cohort. The differences in cardiovascular risk profile between the two genders, such as 243 
lipid levels and blood pressure, may have contr buted to the observed gender-specific association. The 244 
higher CHD incidence rate in men (7.1 per 1000 person years) compared to women (4.0 per 1000 245 
person years), may also be a contributing factor. The lack of a significant association in women might 246 
have been attributable to the smaller number of new CHD event. Adiponectin levels were known to be 247 
higher in women and decline with abdominal adiposity, which also show gender-specific differences 248 
(25, 30). Indeed, adiponectin level was found to be higher in the female subjects of our cohort. 249 
Gender-specific differences in adiponectin levels have been shown to be strongly associated with 250 
serum androgen levels (25). Our group has previously demonstrated that testosterone selectively 251 
decreased the circulating concentrations of the high molecular weight form of adiponectin by 252 
impeding its secretion from the adipose tissue (17). Androgens have been shown to decrease plasma 253 
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adiponectin and the androgen-induced hypoadiponectinaemia may lead to higher risk of 254 
atherosclerosis in men (31). The unfavourable consequences of lower adiponectin levels could 255 
possibly lead to a higher risk of developing CHD in men than in women. Therefore, the genetic effect 256 
of ADIPOQ might be more readily detected in the high risk male subjects. 257 
 258 
We have demonstrated, in this long-term longitudinal study, the independent association of 259 
ADIPOQ +276G>T with incident CHD in a general population. In previous prospective studies which 260 
examined the genetic effect of +276G>T on CHD (11) or CVD (9, 10) development, a US study 261 
based on diabetic men reported a significant association of this SNP with CVD development (9). 262 
Contrary to our findings, they reported that the T allele was associated with a lower risk of CVD and 263 
increased adiponectin level (9). The discrepancy may be explained by the difference in inclusion 264 
criteria (subjects from the general population versus all DM patients and study endpoints (CHD 265 
versus CVD). Two other longitudinal studies (10, 11) did not detect a significant association of 266 
+276G>T, but reported significant associations of rs266729 and rs17300539 (monomorphic in Han 267 
Chinese), with CVD development (10); and rs822395 with CHD risk (11). However, no significant 268 
associations of rs266729 and rs822395 were detected in this study. Ethnic differences in genetic 269 
composition and interaction, together with distinct environmental factors, may contribute to these 270 
variations in findings. 271 
 272 
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The +276G>T variant was located within intron 2 of ADIPOQ. The biological significance of 273 
this SNP and the mechanism of which this variant leads to altered adiponectin levels has not been 274 
fully elucidated. We postulated that it may potentially affect the transcriptional activity or the splicing 275 
efficiency of the ADIPOQ gene. Previous studies have demonstrated that intronic polymorphisms can 276 
influence the transcription activity or splicing processes, even when the variants are located more than 277 
30bp away from the nearest splice junction (32). Intronic splicing control elements, which are 278 
involved in recognition of the appropriate splice site or in regulation of the splice site usage, have 279 
been found as far as 200bp away from the splice site (33). Therefore, the +276G>T variant, which is 280 
located ~60bp away from the nearest splice junction, may potentially affect the splicing efficiency. 281 
Future functional studies would be helpful to delineate the effect of this variant on adiponectin protein 282 
expression.   283 
 284 
This study has several limitations. The relatively small number of incident CHD cases, despite 285 
the long follow-up period, has made this study slightly underpowered. Nonetheless, the current 286 
sample size could achieve over 80% power to detect a significant association of +276G>T with a 287 
large effect size of 1.54 in men, at a significance level of 0.05. On the other hand, the effects of the 288 
other ADIPOQ SNPs may be too modest for a significant association to be detected. This study was 289 
limited by the small number of hard endpoint cases, such as MI, and has therefore made it difficult for 290 
a definitive conclusion to be drawn. Furthermore, the current study would have been significantly 291 
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strengthened with the detailed analyses of more CHD phenotypes. However, as data were retrieved 292 
from the Hospital Authority database, detailed information on coronary disease severity, such as the 293 
degree of coronary stenosis, were not available. Due to the limited plasma samples available for the 294 
analysis of adiponectin levels at baseline, adiponectin levels obtained at CRISPS2 were used as an 295 
alternative to examine the association with the +276G>T variant and incident CHD in the current 296 
study. However, with the small sample size, in particular the limited number of incident CHD cases, 297 
as well as a shorter follow-up interval of ~9.6 year, we were unable to demonstrate a significant 298 
association between CRISPS2 adiponectin level and the development of CHD. Nevertheless, the HRs 299 
were in keeping with the protective effect of adiponectin against CHD development in a general 300 
population initially free of the disease. Furthermore, we have only considered most, but not all, 301 
confounding factors for the development of CHD. Due to the observational study design, detailed 302 
information on lifestyle modification or treatment interventions, including the effects of different drug 303 
used and changing dosage during the study period, which may act as potential confounding factors, 304 
were not available for analyses. Taken into consideration these potential biases, effects of 305 
dysglycaemia (including DM, FPG and 2hrG), hypertension and dyslipidaemia were adjusted for in 306 
the multiple adjustment analyses. Other confounding factors in this observational study, such as the 307 
effect of attrition, may also lead to potential bias. The CRISPS cohort is a population-based study of 308 
the Hong Kong Southern Chinese. The findings from this study may not be generalised to other 309 
nations. Nonetheless, our data represents one of the largest longitudinal cohorts of Chinese subjects 310 
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with a long follow-up period. With the growing epidemic of CHD risk factors, such as DM and 311 
hyperlipidaemia, in the Chinese population, the present findings may still be clinically significant. 312 
Further prospective studies in Chinese, as well as in other populations would be useful to validate our 313 
results. 314 
  315 
In conclusion, this study demonstrated that the +276G>T variant of ADIPOQ, associated with 316 
low circulating adiponectin levels, may be an independent predictor of CHD in community-based 317 
Southern Chinese men initially free of CHD. The current study has provided evidence that low 318 
adiponectin level, as may be affected by a genetic variant in the ADIPOQ gene, confer a greater risk 319 
of CHD. Our data are suggestive of a protective role of adiponectin in CHD development in the 320 
healthy population. Our findings also support the notion that high adiponectin levels are associated 321 
with a lower risk of CHD in healthy populations, whereas high levels in established cardiovascular 322 
disease may reflect a compensatory up-regulation of adiponectin. The +276G>T variant of ADIPOQ 323 
may affect the adiponectin gene expression and may act as a potential genetic marker for the 324 
prediction of CHD. 325 
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Figure legend 457 
 458 
Figure 1. The cumulative survival curves for incident CHD in men, based on multiple Cox 459 
regression model 1, with adjustment for age, BMI, 2hrG, HOMA-IR, HDL-C, LDL-C, TG, SBP, 460 
DBP and smoking. The cumulative survival curves were stratified by the +276G>T genotypes. 461 
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Table 1. Baseline clinical characteristics of subjects. 
 
 All   Male  Female 
Baseline Parameters Non-CHD Incident CHD  Non-CHD Incident CHD  Non-CHD Incident CHD 
n 2012 184  915 111  1097 73 
Sex (Male %) 45.5 60.3**  - -  - - 
Age (year) 44.4±11.7 56.3±10.9**  44.9±12.3 55.6±10.8**  44.0±11.2 57.2±11.0** 
BMI (kg/m
2
) 24.0±3.6 25.8±3.3**  24.3±3.3 25.8±3.3**  23.9±3.7 25.8±3.3** 
Waist circumference (cm) 
M: 82.6±9.1 
F: 74.8±9.0 
M: 88.1±9.5** 
F: 82.5±8.4** 
 
82.5±9.1 88.1±9.5** 
 
74.8±9.0 82.5±8.4** 
Fasting glucose (mmol/l) 5.3±1.1 6.1±2.3*  5.4±1.3 5.8±1.8*  5.2±0.9 6.6±2.9* 
2hr post-OGTT glucose (mmol/l) 6.6±2.7 8.5±5.0**  6.5±3.1 7.9±4.4**  6.7±2.4 9.4±5.9** 
DM (%) 7.1 24.5**  7.8 18.9**  6.5 32.9** 
DM Family history (%)
a 17.4 13.7  15.9 9.2  18.6 20.5 
Fasting insulin (µU/ml)
 b
 4.8(3.1-7.3) 5.7(3.9-9.0) **  3.0(2.0-4.6) 3.7(2.6-5.3)*  3.3(2.3-5.0) 5.1(3.1-6.9)** 
HOMA-IR
a
 1.1(0.7-1.7) 1.5(1.0-2.3) **  0.7(0.4-1.1) 0.9(0.6-1.3)*  0.7(0.5-1.1) 1.2(0.7-1.8)** 
Dyslipidemia (%) 62.4 82.1**  61.9 79.3**  62.9 86.3** 
TC (mmol/l) 5.0±1.0 5.4±1.0**  5.1±1.1 5.3±0.9**  4.9±1.0 5.6±1.1** 
HDL (mmol/l) 1.3±0.3 1.2±0.3**  1.2±0.3 1.1±0.3*  1.4±0.3 1.3±0.3* 
LDL (mmol/l)  3.2±0.9 3.6±1.0**  3.3±0.8 3.5±0.8  3.1±0.9 3.7±1.1** 
TG
b
 (mmol/l) 1.0(0.7-1.4) 1.3(0.9-1.9) *  1.1(0.8-1.6) 1.4(1.0-2.0)*  0.6(0.5-0.9) 0.9(0.6-1.1)* 
SBP
c
 (mmHg)  117.6±18.9 135.1±23.3**  120.0±17.0 133.3±21.2**  115.5±20.0 137.8±25.9** 
DBP
d
 (mmHg) 74.1±10.7 81.2±11.9**  76.6±10.0 81.6±12.4**  72.0±10.9 80.5±11.0** 
HT (%) 14.1 48.4**  14.8 45.9**  13.6 52.1** 
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HT Family history (%)
e
 29.4 24.0  28.7 20.9  30.1 28.8 
Taking anti-hypertensive drug 3.2 12.4**  3.2 8.8*  3.3 17.9** 
Regular exercise (%) 41.5 44.6  44.8 47.7  38.7 39.7 
CHD Family history (%) 10.4 13.8  10.9 5.5  16.2 17.8 
Smoking (%) 22.6 37.2**  45.5 56.8*  3.5 6.9 
Alcohol drinking (%) 36.1 42.9  56.1 59.1  19.4 18.1 
**P-value < 0.001; *P-value < 0.05; Data as mean ± standard deviation or median with interquartile range. 
a
Diabetes in first degree relatives. 
b
Natural-log-transformed before analysis. 
c
SBP + 10mmHg if on anti-hypertensive drug.
 d
DBP + 5mmHg if on anti-hypertensive drug. 
e
Hypertension in first 
degree relatives. BMI: Body mass index; CHD: coronary heart disease; DBP: diastolic blood pressure; DM: type 2 diabetes; F: Female; HDL-C: high-density 
lipoprotein cholesterol; HOMA-IR: homeostasis model assessment index of insulin resistance; HT: hypertension; LDL-C: low-density lipoprotein cholesterol; 
M: Male; n: Number; SBP: systolic blood pressure; TC: total cholesterol; TG: triglyceride.  
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Table 2. Genotype distributions and results of Cox-regression analyses.  
 
SNP  Genotype distribution MAF Unadjusted 
(1/2)  Non-CHD Incident  
CHD 
Non-CHD Incident 
CHD 
HR(95% CI) P-value 
  (11/12/22) (11/12/22)     
rs1501299 All 1103/759/148 88/75/19 0.262 0.310 1.26(1.01-1.56) 0.042 
(+276G>T) M 500/343/71 46/52/11 0.265 0.339 1.39(1.05-1.83) 0.020
a
 
(G/T) F 603/416/77 42/23/8 0.260 0.267 1.04(0.73-1.50) 0.816 
        
rs2241766 All 1007/822/183 89/83/12 0.295 0.290 0.97(0.78-1.22) 0.813 
(T/G) M 466/371/78 56/52/3 0.288 0.261 0.87(0.65-1.18) 0.374 
 F 541/451/105 33/31/9 0.301 0.336 1.16(0.82-1.62) 0.401 
        
rs12495941 All 680/966/362 56/95/32 0.421 0.434 1.05(0.86-1.29) 0.633 
(G/T) M 327/417/168 31/58/21 0.412 0.455 1.15(0.89-1.50) 0.278 
 F 353/549/194 25/37/11 0.427 0.404 0.91(0.65-1.27) 0.592 
        
rs822396 All 1511/468/30 137/46/1 0.131 0.130 0.99(0.73-1.35) 0.955 
(A/C) M 688/213/13 84/26/1 0.131 0.126 0.97(0.65-1.45) 0.878 
 F 823/255/17 53/20/0 0.132 0.137 1.04(0.64-1.67) 0.884 
        
rs822395 All 1441/527/41 130/53/1 0.151 0.149 0.98(0.73-1.31) 0.900 
(A/C) M 654/243/16 81/29/1 0.151 0.139 0.92(0.63-1.36) 0.674 
 F 787/284/25 49/24/0 0.152 0.164 1.08(0.70-1.68) 0.720 
        
rs182052 All 698/966/342 64/93/25 0.411 0.393 0.93(0.76-1.15) 0.510 
(G/A) M 319/436/157 41/53/15 0.411 0.381 0.89(0.68-1.17) 0.400 
 F 379/530/185 23/40/10 0.411 0.411 1.00(0.72-1.39) 0.992 
        
-10677C>Tb All 1755/248/8 156/25/3 0.066 0.084 1.26(0.87-1.83) 0.225 
(C/T) M 797/114/4 90/20/1 0.067 0.099 1.48(0.96-2.30) 0.078 
 F 958/134/4 66/5/2 0.065 0.054 0.86(0.42-1.75) 0.671 
        
rs266729 All 1148/729/130 111/65/8 0.246 0.220 0.88(0.69-1.12) 0.288 
(C/G) M 512/347/53 67/40/4 0.248 0.216 0.84(0.61-1.16) 0.298 
 F 636/382/77 44/25/4 0.245 0.226 0.92(0.63-1.34) 0.653 
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rs16861194 All 1410/543/59 128/50/6 0.164 0.168 1.03(0.78-1.34) 0.854 
(A/G) M 642/248/25 80/28/3 0.162 0.153 0.94(0.65-1.35) 0.723 
 F 768/295/34 48/22/3 0.165 0.191 1.17(0.78-1.76) 0.438 
a
Remained significant after adjustment for age and BMI. 
b
No rs number is assigned for this SNP.  
1: Major allele; 2: Minor allele; F: Female; M: Male; MAF: Minor allele frequency. 
Page 30 of 34
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
Table 3. Multiple Cox regression analyses of ADIPOQ +276 G>T and incident CHD in the male subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model 1: Multiple adjustments made for age, BMI, 2hrG, HOMA-IR, HDL-C, LDL-C, TG, SBP, DBP and Smoking. Model 2: Multiple adjustments made 
for age, BMI, FPG, 2hrG, HDL-C, LDL-C, TG, SBP, DBP and Smoking. Model 3: Multiple adjustments made for age, BMI, DM, dyslipidemia, HT and 
smoking. aNatural-log-transformed before analysis. bSBP + 10mmHg and DBP + 5mmHg if on anti-hypertensive drug. 2hrG: 2hr post-OGTT glucose; BMI: 
Risk factors Model 1  Model 2  Model 3 
HR (95%CI) P-value  HR (95%CI) P-value  HR (95%CI) P-value 
+276G>T (T) 1.54(1.13-2.08) 5.5x10-3  1.44(1.08-1.93) 0.015  1.39(1.05-1.84) 0.023 
Age (years) 1.06(1.04-1.08) <0.001  1.06(1.04-1.08) <0.001  1.06(1.04-1.08) <0.001 
BMI (kg/m
2
) 1.07(1.00-1.15) 0.044  1.08(1.02-1.15) 0.010  1.10(1.03-1.16) 0.002 
DM - -  - -  1.01(0.61-1.68) 0.976 
FPG (mmol/l) - -  1.11(0.90-1.37) 0.331  - - 
2hrG (mmol/l) 1.00(0.95-1.05) 0.954  0.98(0.90-1.06) 0.562  - - 
HOMA-IR
a
 1.06(0.77-1.48) 0.711  - -  - - 
Dyslipidemia - -  - -  1.43(0.89-2.31) 0.143 
HDL-C (mmol/l) 0.62(0.26-1.50) 0.292  0.57(0.24-1.32) 0.188  - - 
LDL-C (mmol/l) 0.91(0.71-1.17) 0.467  0.92(0.73-1.17) 0.504  - - 
TG (mmol/l)
a
 1.40(0.85-2.31) 0.187  1.40(0.86-2.28) 0.177  - - 
HT - -  - -  2.03(1.31-3.14) 0.002 
SBP
b
 (mmHg) 1.01(0.99-1.03) 0.237  1.02(1.00-1.03) 0.088  - - 
DBP
b
 (mmHg) 1.01(0.97-1.04) 0.744  1.00(0.97-1.03) 0.791  - - 
Smoking 1.25(0.96-1.88) 0.278  1.30(0.88-1.92) 0.183  1.82(0.88-1.91) 0.185 
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Body mass index; CI: Confidence interval; DM: type 2 diabetes; DBP: diastolic blood pressure; FPG: fasting plasma glucose; HOMA-IR: homeostasis model 
assessment index of insulin resistance; HR: Hazard ratio; HT: hypertension; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein 
cholesterol; SBP: systolic blood pressure; TG: triglyceride.  
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Supplementary table 1. Comparison of CRISPS2 adiponectin levels between different 
genotypes of +276G>T. 
 
 
 +276G>T 
 GG GT TT 
All (n=1676) 921 633 122 
Adiponectin level (mg/l) 6.92(4.41-10.90) 6.64(4.28-10.08) 6.18(3.85-9.11) 
    
Men (n=804) 433 307 64 
Adiponectin level (mg/l) 5.89(3.59-9.47) 5.43(3.62-8.36) 4.93(3.62-7.19) 
    
Women (n=872) 488 326 58 
Adiponectin level (mg/l) 7.96(5.39-11.88) 7.93(5.39-11.75) 7.60(4.90-11.30) 
Adiponectin levels at CRISPS2 were natural-log-transformed before analysis and data was  
presented as median with interquartile range. 
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